- First patient enrolled in Phase 1b/2 NX-5948-203 study
- Study evaluates bexobrutideg + venetoclax in relapsed/refractory CLL
- Study conducted under Nurix-Roche global collaboration
- Potential expansion to first-line CLL and other B-cell malignancies
- Data to inform registrational development strategies
- Nurix Therapeutics announced the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an oral BTK degrader, in combination with venetoclax for patients with relapsed/refractory CLL. The study is part of the global collaboration with Roche and may expand to first-line CLL and other B-cell malignancies. Data from the trial will inform future registrational strategies.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card